Pharma under scrutiny by US Justice Department
This article was originally published in SRA
Executive Summary
The pharmaceutical industry’s compliance with the Foreign Corrupt Practices Act will come under close scrutiny from the US Department of Justice in the months and years ahead, says the head of the department’s Criminal Division1.